Unknown OBSERVATIONAL NCT05010330

Identify Prognostic Biomarkers of Lung Cancer

Multi-omics Combined With Clinical Data Analysis to Identify Prognostic Biomarkers of Lung Cancer

Sponsor: RenJi Hospital

Conditions Lung Adenocarcinoma Lung Cancer Lung Squamous Cell Carcinoma Non Small Cell Lung Cancer

Updated 5 times since 2021 Last updated: Aug 14, 2021 Started: Jul 1, 2020 Primary completion: Sep 20, 2021 Completion: Sep 30, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Lung Adenocarcinoma and Lung Cancer and is currently ongoing. RenJi Hospital leads this study, which shows 5 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Sep 2023 — Jul 2024 [monthly]

Unknown Status

Status: Recruiting → Unknown Status
Dec 2021 — Sep 2023 [monthly]

Recruiting
Sep 2021 — Dec 2021 [monthly]

Recruiting

First recorded

Jul 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

RenJi Hospital

Data source: RenJi Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China